Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. develops clinical-stage therapies for unmet medical needs, with news centered on pipeline progress, regulatory authorizations, intellectual property and financing activity. Company updates frequently cover HT-001, a topical therapeutic for EGFR inhibitor-associated skin toxicities in cancer patients, as well as HT-VA/GDNF metabolic research tied to obesity, MAFLD and related liver-fat pathways.
Other HOTH news themes include patent protection for mast-cell targeting splice-switching oligonucleotide technology, use of the OpenClaw AI-enabled platform for drug-discovery analysis, and capital formation through registered direct offerings and warrant issuances. The company’s public updates generally reflect early-stage pharmaceutical research moving from preclinical work into clinical development.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a licensing agreement for a medical device that enables rapid COVID-19 diagnostics via breath samples. Developed in collaboration with George Washington University, the device utilizes nanotechnology and AI to deliver immediate results, allowing public health professionals to conduct point-of-care testing efficiently. The initiative aims to create real-time data tracking for COVID-19 infections, enhancing public health responses during the pandemic. CEO Robb Knie emphasized the device's potential to mitigate COVID-19 spread significantly.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire rights to VNLG-152, a novel retinamide for dermatological diseases. This agreement follows an earlier Letter of Intent and enables Hoth to receive royalties from Isoprene’s usage of VNLG-152 in oncology. UMB researchers have validated RAMBAs’ effectiveness against breast and prostate cancer, showing superior effects compared to approved retinoids. Hoth aims to address dermatological disorders while mitigating adverse effects associated with traditional retinoid therapies.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a sponsored research agreement with Virginia Commonwealth University (VCU) aimed at developing a potential treatment for COVID-19. Led by Dr. Michael Peters, the research focuses on optimizing peptide biomimetics to enhance their binding rates to the SARS-CoV-2 spike protein. The project is expected to leverage advanced computational resources to improve peptide stability and efficacy. Hoth has an exclusive license for this innovative COVID-19 therapeutic.
Hoth Therapeutics (NASDAQ: HOTH) announced an expanded research agreement with George Washington University to investigate WEG232 for treating dermatological side effects related to chemotherapy and immunotherapy. The company aims to request a Pre-IND meeting with the FDA by year-end. WEG232 has shown promise in reducing erlotinib-induced facial rash by approximately 71%. Future studies will explore optimal application timing and its effects on inflammation. CEO Robb Knie expressed optimism about advancing this much-needed therapeutic for cancer patients.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the publication of a white paper by Scientific Advisory Board member Dr. Michael H. Peters, detailing mappings of the COVID-19 virus spike protein. The company has licensed exclusive technology from VCU for a novel peptide therapeutic aimed at preventing spike protein binding, potentially slowing COVID-19 transmission. This peptide binds with high affinity to the SARS-CoV-2 spike protein, blocking its attachment to human cells. Hoth is also advancing its pipeline focused on dermatological disorders and COVID-19 vaccine prospects.